Greenwich LifeSciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; financial statements are unaudited. Greenwich is a clinical-stage biotechnology company developing GP2, combined with GM-CSF as GLSI-100, to prevent breast cancer recurrence. The company reports no product revenue. It has commenced the Flamingo-01 Phase III trial.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.380 million | $0.633 million | $3.207 million | $2.294 million |
| General and administrative | $0.368 million | $0.140 million | $0.781 million | $0.468 million |
| Total operating expenses | $1.748 million | $0.773 million | $3.989 million | $2.763 million |
| Net loss | $1.628 million | $0.746 million | $3.753 million | $2.716 million |
| Net loss per share, basic and diluted | $0.13 | $0.06 | $0.29 | $0.21 |
- Cash: $10.944 million at June 30, 2023, down from $13.468 million at December 31, 2022. Six-month cash used in operating activities was $2.524 million; there was no investing or financing cash flow in the period.
- Balance sheet: Total assets were $10.951 million; total liabilities were $0.302 million, including $0.221 million of accrued interest payable to HJF. Stockholders’ equity was $10.650 million. The balance sheet reports no borrowings or other debt balance.
- Margins: Not meaningful because the company had no revenue. Interest income was $119,453 for Q2 and $235,633 for the first half.
- Management stated existing cash was expected to fund planned operations for the next 12 months from issuance of the financial statements, while also saying additional capital will be required for long-term operating needs.
Material changes and outlook
- Q2 operating expenses rose 126% year over year, and net loss increased 118%. For the first half, operating expenses rose 44% and net loss increased 38%.
- Management attributed higher R&D spending to compensation, clinical, and manufacturing costs; higher G&A spending to compensation, financing, and corporate costs.
- The company expects continued losses and significant spending on development, clinical trials, manufacturing, and operations. It may seek additional capital through equity or debt; management gave no assurance that financing will be available.
- Material commitments include the GP2 license from HJF and manufacturing and clinical-trial obligations related to the planned Phase III trial. The company relies on third-party manufacturers for clinical-trial materials and product.
- The board’s stock repurchase authorization expired March 31, 2023. No shares were repurchased in the first half of 2023; cumulative repurchases were approximately $7.536 million.
Risks, contingencies, and controls
- The filing reports no material legal proceedings and no material change to the risk factors in the 2022 Form 10-K.
- Disclosure controls and procedures were deemed ineffective as of June 30, 2023 due to material weaknesses, including inadequate segregation of duties and insufficient written accounting, IT, and financial-reporting procedures. Management was developing a remediation plan.
- Management identified no material contractual obligations beyond employment and shareholder agreements, the HJF license, and manufacturing and clinical-trial obligations; no off-balance-sheet arrangements were reported.
- The company reported no material impact from adopting the expected-credit-loss accounting standard in January 2023.
Key facts for investors to verify
- Flamingo-01 trial progress, enrollment, costs, and any changes to its timeline or design.
- Cash burn and whether available cash remains sufficient for the stated 12-month operating period; financing needs and availability.
- Clinical, manufacturing, and license-related commitments, including accrued HJF interest obligations.
- Progress in remediating the disclosed internal-control material weaknesses.
- Future expense trends, stock-based compensation, and any additional equity issuance or dilution.